- Home
- CRIS vs SCNX Comparison
CRIS vs SCNX Comparison
Compare CRIS & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | SCNX |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 16.2M |
| IPO Year | 2000 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CRIS | SCNX |
|---|---|---|
| Price | $1.37 | $0.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $17.00 | $1.50 |
| AVG Volume (30 Days) | 283.3K | ★ 696.8K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,898,000.00 | $3,831,778.00 |
| Revenue This Year | $27.10 | $1,097.38 |
| Revenue Next Year | $67.74 | $239.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 31.50 | 30.72 |
| 52 Week Low | $0.18 | $0.24 |
| 52 Week High | $6.74 | $2.60 |
Technical Indicators
Market Signals| Indicator | CRIS | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 26.19 | 40.57 |
| Support Level | $0.80 | $0.30 |
| Resistance Level | $1.42 | $0.43 |
| Average True Range (ATR) | 0.14 | 0.03 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 3.73 | 11.30 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.